Doxorubicin (DOX) is a widely prescribed antineoplastic and although the precise mechanism(s) have yet to be identified, DOX-induced oxidative stress to mitochondrial membranes is implicated in the pathogenic process. Previous attempts to protect against DOX-induced cardiotoxicity with a-tocopherol (vitamin E) have met with limited success, possibly as a result of inadequate delivery to relevant subcellular targets such as mitochondrial membranes. The present investigation was designed to assess whether enrichment of cardiac membranes with a-ocopherol is sufficient to protect against DOX-induced mitochondrial cardiotoxicity. Adult male Sprague-Dawley rats received seven weekly subcutaneous injections of 2 mg/kg DOX and fed either standard diet or diet supplemented with a-tocopherol succinate. Treatment with a cumulative dose of 14 mg/kg DOX caused mitochondrial cardiomyopathy as evidenced by histology, accumulation of oxidized cardiac proteins, and a significant decrease in mitochondrial calcium loading capacity. Maintaining rats on the a-tocopherol supplemented diet resulted in a significant (two-to fourfold) enrichment of cardiac mitochondrial membranes with a-tocopherol and diminished the content of oxidized cardiac proteins associated with DOX treatment. However, dietary a-tocopherol succinate failed to protect against mitochondrial dysfunction and cardiac histopathology. From this we conclude that although dietary vitamin E supplementation enriches cardiac mitochondrial membranes with a-tocopherol, either (1) this tocopherol enrichment is not sufficient to protect cardiac mitochondrial membranes from DOX toxicity or (2) oxidative stress alone is not responsible for the persistent mitochondrial cardiomyopathy caused by long-term DOX therapy.
Introduction
Doxorubicin (DOX; Adriamycin ® ) is a highly potent anthracycline antineoplastic widely prescribed for treating a variety of cancers including both solid tumors and leukemias. Unfortunately, the clinical utility of DOX in cancer chemotherapy is limited by the development of a cumulative and irreversible dilated cardiomyopathy in a high percentage of patients receiving a total dose exceeding 550 mg/m 2 . This cardiomyopathy is manifested histomorphologically as vacuolization of the sarcoplasmic reticulum and the appearance of enlarged mitochondria with highly disrupted and disorganized cristae (1, 2) . Functionally, there occurs a dose-dependent and progressive decline in maximum developed force of the myocardium reflected by a decreased ejection fraction accompanied by a corresponding increase in left-ventricular end-diastolic volume and pressure (3, 4) . Left untreated, patients eventually develop classical symptoms of terminal congested heart failure, which is unresponsive to standard positive inotropic therapeutic management.
Over the past 25 yr, considerable research has been conducted to explore the mechanism(s) of DOXinduced cardiomyopathy (5) . The drug has been demonstrated to cause a number of potentially pathological effects. However, it is still uncertain what role these varied events play in the pathogenic process. Despite the fact that the precise mechanism(s) of toxicity is unknown, it is widely accepted that the drug stimulates the generation of oxygen free radicals and that oxidative stress is an central feature of DOXinduced cardiac toxicity (6-10). It is not known, however, whether oxidative injury is the cause or a consequence of the toxicity.
Detailed investigations have revealed that DOX accepts electrons from complex I of the mitochondrial respiratory chain to form the unstable semiquinone free radical of the drug (5, 11, 12) . Subsequent auto-oxidation of the semiquinone occurs through transfer of the unpaired electron to molecular oxygen to regenerate the parent drug at the expense of reducing oxygen to the highly reactive superoxide anion free radical. Superoxide radicals are toxic themselves or can be further reduced to hydrogen peroxide and hydroxyl free radical, either of which may be the ultimate reactive species. It is believed that this stimulation of free radical generation is responsible for the observed oxidative tissue damage associated with DOX drug treatment. Such damage includes accumulation of products of lipid peroxidation (13) (14) (15) , oxidized DNA (16) (17) (18) (19) (20) , and protein adducts (21, 22) . The literature abounds with implications of these various forms of oxidative stress as being precipitous to DOX-induced cardiac toxicity.
Numerous attempts have been made to prevent DOX cardiotoxicity by co-administering antioxidant agents. Examples include N-acetyl cysteine, vitamins C (ascorbate) and E (a-tocopherol), ebselen, selenium, carvedilol, and the metal ion chelator Dexrazoxane. With the exception of carvedilol and Dexazoxane, the results have been highly variable and disappointing. One explanation for this varied success has been the ineffective delivery of the selected antioxidant to critical subcellular targets, which in this case are cardiac mitochondrial membranes. One strategy to resolve this problem is to design treatments that specifically enrich cardiac membranes with antioxidant agents. For example, to deliver nonenzymatic antioxidants selectively to mitochondria, investigators (23) have attached a lipophilic triphenylphosphonium cation to a-tocopherol (MitoVit E) or to ubiquinone (MitoQ). The positive charge of these antioxidant derivatives enables them to accumulate several hundred-fold within mitochondria due to the negative membrane potential inside mitochondria. Cell culture studies using these mitochondria-targeted antioxidants have clearly demonstrated the protective abilities of these molecules against toxic oxidative stress (23,24). Other mitochondria-targeted antioxidants include synthetic peptides that selectively concentrate in the inner mitochondrial membrane. These peptides have been shown to scavenge reactive oxygen species at the site of production, thereby limiting mitochondrial oxidative damage and cell death. Using these cytoprotective peptides, investigators have shown that mitochondrial oxidative stress and damage are responsible for hydrogen peroxide-and 3-nitropropionic acid-induced cell death as well as myocardial ischemia/reperfusion injury (25). Fariss et al. have also demonstrated that the in vivo or in vitro administration of D-a-tocopheryl succinate (parenteral or dietary) results in a four-to eightfold enrichment of hepatic mitochondria with endogenous a-tocopherol, which appears to be responsible for protecting hepatocytes against toxic oxidative stress including that which results from treatment with DOX (26) . However, it is not known whether these vitamin E succinate treatments are able to enrich cardiac mitochondria with protective levels of a-tocopherol.
Therefore, the purpose of this investigation was to evaluate the cardioprotective potential of dietary a-tocopheryl succinate supplementation against the mitochondrial-associated cardiac toxicity of subchronic DOX administration to rats. Full characterization included three specific elements: (1) demonstration of effective enrichment cardiac mitochondrial membranes with a-tocopherol, 2) inhibition of oxidative tissue injury, and (3) prevention of the mitochondrial dysfunction and histopathology associated with DOX-induced cardiotoxicity.
Materials and Methods

Reagents
Injectable-grade DOX was purchased from a commercial source (Henry Schein Inc., NY). All chemicals were of analytical grade or higher unless noted otherwise.
Animal and Treatment Regimen
Sprague-Dawley rats (Harlan, WI) were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility with free access to food and water. All rats were allowed to acclimate for at least 5 d prior to initiation of the study. Adult male rats initially weighing 150-175 g were randomly assigned to one of four treatment groups (n = 12). Animals in the tocopherol groups were fed Purina ® Rat Chow ® (Purina Mills, LLC) supplemented with 2 g D-a-tocopheryl succinate (TOCO)/kg diet, 1 wk prior to the initiation of DOX injections. After 1 wk of feeding with the TOCO diet, animals received seven weekly subcutaneous injections of 2 mg/kg DOX dissolved at 2 mg/mL in saline or an equivalent volume of saline. Dorsal injection sites were rotated to avoid local tissue necrosis. Rats were maintained on the diet and killed by decapitation 1 wk after the final injection. No mortality was observed during the course of the experiment in any of the treatment groups. Heart, liver, and serum samples were collected immediately after animals were killed and the hearts' weights were quickly recorded. A lateral slice of heart ventricular tissue was taken for light microscopy and a small piece was removed and frozen for later analysis in the reactive carbonyls assay; the remaining tissue from three hearts in the same treatment group was pooled for use in the following experiments. Liver and serum samples were quick frozen in liquid nitrogen and stored at -80°C until analyzed further.
Mitochondrial Isolation
Hearts from three animals were pooled and minced. Tissue was homogenized in 10 volumes of isolation buffer (250 mM Sucrose, 1 mM ethyleneglycol tetraacetic acid [EGTA], 10 mM HEPES, pH 7.4) supplemented with 10 U protease (subtilisin Carlsberg)/g tissue in a Teflon on glass homogenizer. One hundred microliters of homogenate was removed and stored at -80°C until used for a-tocopherol analysis. The remaining homogenate was centrifuged at 10,000g for 10 min at 4°C. Supernatants were discarded and pellets were resuspended in isolation buffer and centrifuged at 1,000g for 10 min at 4°C. The supernatant was centrifuged at 9,500g to sediment mitochondria. The resulting mitochondrial pellet was washed in isolation buffer lacking EGTA and sedimented at 9,500g for a total of two times. The resulting mitochondrial pellet (standard mitochondrial preparation) was suspended at a protein concentration of approx 40 mg/mL in isolation buffer lacking EGTA. Onehalf of the standard mitochondrial preparation was carried through additional purification steps while the other half was set aside for experiments described later.
Further purification of mitochondria was accomplished using percoll gradient separation according to the procedure of Hovius et al. (27) , with minor modifications. Standard mitochondrial preparations were layered onto a continuous percoll gradient buffer (30% Percoll, 225 mM sucrose, 25 mM HEPES, 1 mM EGTA, 0.1% bovine serum albumin, pH 7.4) and centrifuged at 95,000g for 30 min at 4°C. This purified mitochondrial fraction was centrifuged at 6,300g for 10 min at 4°C to remove any Percoll. Pure mitochondrial pellets were resuspended in isolation buffer without EGTA.
Mitochondrial Oxygen Consumption
Oxygen consumption by mitochondria was monitored using an oxygen electrode and oxymeter (Yellow Springs, CO.) attached to a strip chart recorder. To 1.0 mL of respiration buffer (100 mM KCl, 50 mM sucrose, 10 µM EGTA, 10 mM Tris, 2.5 mM KH 2 PO 4 , pH 7.4) containing either glutamate/malate at 10 mM each or 10 mM succinate with 2 µM rotenone, 0.25 mg protein from the standard mitochondrial preparation was added. Oxygen tension in the solution was recorded for several minutes to establish a baseline before adding 90 nmol ADP to initiate state 3 respi-
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Mitochondrial Calcium Loading Capacity
Mitochondrial calcium loading capacity was estimated using a spectrophotometric assay employing the metallochromatic dye arsenazo III as described earlier (29, 30) . Briefly, Arsenazo III was used at a final concentration of 100 µM in an assay buffer containing 200 mM sucrose, 10 mM Tris, 10 µM EGTA, and 5 mM KH 2 PO 4 (pH 7.4). To 1.0 mL of assay buffer, 0.25 mg protein from the standard mitochondrial preparation was added and the suspension was monitored at 662 nm (Arsenazo-calcium complex) and 750 nm (mitochondrial swelling) for approx 1 min in order to obtain a baseline. Calcium was then added in 20 nmol increments to calibrate for the absorbance change per nmol calcium. Mitochondria were then energized with 10 mM succinate plus 2 µM rotenone to initiate calcium uptake. Uptake of calcium was monitored continuously until its complete release back into the medium, which occurred approx 30 minutes after the addition of succinate. Data with cyclosporine A was generated in the same fashion, using 1.0 µM final concentration. Calcium loading capacities were calculated and expressed as nmols calcium/ mg protein.
Protein Carbonyls
Protein carbonyl content was determined in whole heart tissue as described by Levine et al. (31) , with modifications. Heart tissue weighing approx 100 mg was homogenized in 3 volumes of homogenization buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM KCl, 2 mM KH 2 PO 4 , 0.6 mM MgSO 4 , 1.1 mM ethylenediamine tetraacetic acid [EDTA], pH 7.4). Two aliquots containing approx 16 mg tissue each were taken from each sample homogenate and proteins were precipitated in ice-cold trichloroacetic acid (10% w/v). Following incubation at 4°C for 10 min, samples were centrifuged at 11,000g for 3 min. One of the resulting protein pellets was re-suspended in 0.5 mL of 0.2% (w/v) 2,4-dinitrophenylhydrazine (DNPH)/2 M HCl while the other pellet (to serve as a blank) was re-suspended in 0.5 mL of 2 M HCl. Samples were continuously mixed at room temperature for 1 h, after which the reaction was stopped with 0.5 mL of 10% (w/v) trichloroacetic acid. Samples were then centrifuged at 11,000g for 3 min. Pellets were re-suspended and washed with 1 mL of ethanol-ethyl acetate (1:1 v/v) to remove excess DNPH, allowed to stand for 10 min at room temperature, and then centrifuged for 5 min at 11,000g. The supernatant was discarded and the washing procedure was repeated twice for a total of three washings. The resulting protein pellet was dissolved in 1.0 mL of 6 M guanidine in 20 mM sodium phosphate buffer (pH 6.5). Samples were allowed to stand for 10 min at room temperature before reading the absorbance at 360 nm and 280 nm. Protein carbonyl content, expressed as nmol/mg protein was determined from the absorbance ratio 360/280 after subtracting each sample's blank. flow-rate of 1.8 mL/min. A 210 nm excitation wavelength and a 300 nm emission filter were used for all tocopherol determinations.
Light Microscopy
For light microscopy, small blocks of left-ventricular tissue were fixed in 2.5% glutaraldehyde/ 2% formaldehyde in 0.1 phosphate buffer, pH 7.4. Tissues were postfixed in 1% OsO 4 in phosphate buffer then dehydrated in graded acetone solutions and embedded in epon-araldite. Sections with a thickness of 1 µm were stained with 0.25% toluidine blue in 1% sodium borate at 55°C after treatment with 0.1 N HCl and 1% ruthenium red. Stained sections were examined for histopathological evidence of cardiomyopathy by recording the number of damaged cardiomyocytes in a 202,500 µm 2 total crosssectional region of ventricular wall counted with the aid of an eyepiece grid. These counts were used to compute the mean number of myocytes that were damaged per unit area, resulting in the cell damage score reported later (see "Histopathology"). In addition, tissue was scored according to the 0-3 scale derived from the method of Billingham et al. 
Protein Determination
Protein determination was performed as described by Bradford (35) using bovine serum albumin as the standard.
Statistics
Data was analyzed using a two-way analysis of variance (ANOVA) followed by the Fisher's least significant difference (LSD) test using a = 0.05. Values are presented as the mean ± S.E.M. Table 1 summarizes the effect of the tocopherolsupplemented diet on heart and body weights of rats in each of the four treatment groups. The tocopherol-supplemented diet alone had no effect on body or heart weights of animals (SAL + REG vs SAL + TOCO). Rats receiving the DOX + REG regimen showed a characteristic decrease in body weight gain, although no significant decrease in heart weight was observed. The DOX + TOCO group also demonstrated a decrease in body weight gain along with a significant decrease in heart weight when compared to the respective saline control (DOX + SAL). The heart-to-body weight ratio was unaffected in either treatment group.
Results
Animal Body and Heart Weights
a a a a a-Tocopherol Enrichment
The a-tocopherol content of several tissue fractions are shown in Table 2 . In control animals, the TOCOsupplemented diet resulted in an approximately twofold increase in D-a-tocopherol levels in whole heart homogenate and heart mitochondria. In DOX-treated Reported values are the mean ± S.E.M. for n = 12. *Statistical significance compared with respective diet control with a = 0.05 using Fisher's least significant difference (LSD) method of multiple pairwise comparison. HW, heart weight; BW, body weight; SAL + REG, rats receiving saline injections and fed regular Purina ® Rat Chow ® ; SAL + TOCO, rats receiving saline and Purina Rat Chow supplemented with TOCO; DOX + REG, rats receiving DOX and regular chow; DOX + TOCO, rats receiving DOX and the TOCO diet.
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Humana Press Volume 5, 2005 animals, the tocopherol enrichment of mitochondria was increased three-to fourfold (as compared with control or DOX-treated animals on a control diet). Interestingly, rats fed the regular diet and treated with DOX had a dramatic increase (sixfold) in serum D-a-tocopherol content (SAL + REG vs DOX + REG). In addition, animals receiving the supplemented diet also displayed significant increases in D-a-tocopherol content with the addition of DOX treatment (SAL + TOCO vs DOX + TOCO) in both serum and liver samples as depicted in Table 2 .
Mitochondrial Oxygen Consumption
Mitochondria isolated from heart tissue were used to generate data outlined in Table 3 . TOCO apparently did not ameliorate the inhibitory effect of DOX on glutamate/malate-linked phosphorylating respiration, because both DOX groups, DOX + REG and Reported values are the mean ± S.E.M. for n = 4. SAL + REG, rats receiving saline injections and fed regular Purina ® Rat Chow ® ; SAL + TOCO, rats receiving saline and Purina Rat Chow supplemented with D-a-tocopherol succinate (TOCO); DOX + REG, rats receiving doxorubicin (DOX) and regular chow; DOX + TOCO, rats receiving DOX and the TOCO diet.
a Statistical significance as compared with the respective diet control group. b Statistical difference from the respective drug control treatment using Fisher's least significant difference (LSD) method with a = 0.05. Values are in units of nanoatoms of oxygen consumed/min/mg mitochondrial protein and represent the mean ± S.E.M. of n = 4. SAL + REG, rats receiving saline injections and fed regular Purina ® Rat Chow ® ; SAL + TOCO, rats receiving saline and Purina Rat Chow supplemented with D-a-tocopherol succinate (TOCO); DOX + REG, rats receiving doxorubicin (DOX) and regular chow; DOX + TOCO, rats receiving DOX and the TOCO diet.
*Statistical difference with respect to the corresponding SAL control group using Fisher's least significant difference (LSD) with a = 0.05.
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Humana Press Volume 5, 2005 DOX + TOCO, displayed a decrease in state 3 respiration. State 4 respiration with glutamate/malate as the substrate was decreased in the DOX + REG group and remained unchanged in the DOX + TOCO group when compared with their respective saline controls. Succinate-linked respiration was also evaluated, and there was no effect of either DOX or TOCO on state 3. However, DOX treatment caused a decrease in state 4 respiration, which was not restored with the TOCO diet. The RCRs with glutamate/malate were unchanged between all groups; however there was a slight increase in both DOX groups using succinate as the substrate. Overall, there was no statistical difference between the DOX + REG and DOX + TOCO groups for any of the respiration parameters measured. There was no difference in mitochondrial yield from any of the treatment groups (data not shown).
Calcium Loading Capacity
Calcium loading capacity was determined in freshly isolated cardiac mitochondria as a measure of mitochondrial function. As shown in Fig. 1 , diminished calcium loading capacities due to DOX treatment were present in heart mitochondria. The DOX + REG group had a significantly lower calcium loading capacity (approx 40% of the control value), which was not prevented with the TOCO diet. The addition of cyclosporine A inhibited the calcium-induced calcium release from mitochondria in both of the DOX treatment groups, resulting in an increased calcium capacity with no difference from control values.
Histopathology
Light microscopy slides of cardiac tissue from both drug control groups (SAL + REG and SAL + TOCO) were similar and exhibited normal morphology (Fig. 2, left top and bottom panel) . However, samples taken from DOX-treated rats either with or without dietary supplementation of TOCO displayed altered morphology. This altered morphology was manifested as an increased occurrence of myocytes with extensive vacuolization, indicative of DOXrelated cardiomyopathy (Fig. 2, right top and bottom  panel) . The histopathology scores determined as described under "Materials and Methods" are tabulated in Fig. 2 . The score of 0 for the control group is representative of a combined score for SAL + REG and SAL + TOCO samples, because there was no difference between the groups. Cardiac tissue examined from both DOX groups had significantly greater numbers of damaged myocytes present. The Billingham grade for the tissue examined was 1 for each of the two DOX groups (5% or less of total number of cells per block exhibiting early myofibrillar loss and/or Fig. 1 . Calcium loading capacity of isolated rat heart mitochondria as described under "Materials and Methods." Bars represent the mean ± S.E.M for n = 4. *Denotes significance as compared to the respective saline control and † denotes significance as compared to the same sample without the addition of cyclosporine A (CyA) as determined by the Fisher's least significant difference (LSD) method (a = 0.05).
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Humana Press Volume 5, 2005 cytoplasmic vacuolization), suggesting increased cardiomyocyte damage as well (data not shown). Figure 3 shows the reactive carbonyl content of whole heart tissue. Rats receiving DOX alone had a nearly threefold increase of reactive carbonyl content in heart tissue, which was statistically significant when compared to control. However, the a-tocopherol-supplemented group receiving DOX treatment apparently did not have an increase in reactive carbonyl content, because values were not significantly different from controls.
Protein Carbonyls
Discussion
Acute and chronic administration of DOX results in the accumulation of lipid, protein, and DNA oxidation products in cardiac tissue in vivo accompanied by mitochondrial failure and cardiac histopathology. These observations could be regarded as substantiating evidence for oxidative stress being associated, perhaps causally, with drug toxicity (10, 36, 37) . The question that has eluded investigators is whether oxidative stress is the cause or consequence of DOX toxicity. If causative, one would suspect that antioxidant therapy would be effective in preventing and/or Vacuolized myocytes are present in both DOX groups as indicated by arrows. No differences were found between TOCO treatments of either the saline-injected (SAL) or DOX group. Magnification = 1400´. Insert summarizes histopathology scores where the cell damage score represents the mean ± S.E.M. with n = 5 for both DOX groups and n = 6 for control (values were pooled for both SAL groups). *Indicates statistical difference from control (a = 0.05).
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Humana Press Volume 5, 2005 ameliorating DOX-induced cardiomyopathy. Oxidative damage is evidenced in the present investigation by the accumulation of oxidized proteins in cardiac tissue from DOX treated rats maintained on the standard diet. Prevention of the accumulation of these products by dietary supplementation with TOCO indicates that enrichment of cardiac membranes with TOCO was successful.
In accordance with previous investigations, chronic treatment of rats with DOX not only was associated with oxidative stress, but also caused mitochondrial dysfunction and associated histopathological changes to cardiac tissue. We previously reported that chronic DOX treatment regimen results in an inhibition of state 3 and stimulation of state 4 respiration for mitochondria isolated from treated animals as compared to saline-injected controls (38, 39) . Furthermore, the associated cardiac histopathology show a profound subsarcolemma vacuolarization with distinct and abundant mitochondrial enlargement with disorganized and fragmented intramitochondrial cristae (38, 40, 41) .
The present study clearly demonstrates that feeding rats a diet supplemented with 2 g TOCO/kg diet results in a twofold increase in heart mitochondrial a-tocopherol content and an inhibition of oxidative injury in cardiac tissue, but does not protect against DOX-induced mitochondrial dysfunction or cardiomyopathy. The recent study of Exon et al. (42) supports our finding that dietary supplementation with TOCO (similar dose) results in an approximately twofold increase in heart a-tocopherol levels. However, we believe this study is the first demonstration of enrichment of cardiac mitochondrial membranes following dietary TOCO administration. Based on the previous hepatic studies of Fariss et al., it is not surprising that a twofold enrichment of cardiac mitochondria with a-tocopherol did not protect the heart against DOX-induced toxicity. In these previous studies, Fariss et al. (26, 43) demonstrated that an 8-to 10-fold increase in hepatic mitochondrial a-tocopherol levels was required for complete protection of the inner mitochondrial membrane and hepatocytes against a toxic oxidative challenge. In fact, a twofold enrichment of hepatic mitochondria with atocopherol provides only modest protection against iron-induced toxicity in hepatocytes and in the susceptibility of inner mitochondrial membranes to lipid peroxidation. Although the present study clearly demonstrates the inability of dietary vitamin E succinate supplementation to protect against DOX-induced cardiomyopathy, the development of new strategies for the cardiac mitochondrial delivery of a-tocopherol at higher enrichment levels (8-to 10-fold) may still offer cardioprotection during DOX therapy.
Of particular note is the significant augmentation of serum a-tocopherol, not only by dietary supplementation, but also by DOX treatment itself. Although this may reflect an increase in a-tocopherol-specific activity in serum lipids, it more likely is a consequence Fig. 3 . Protein carbonyl content of whole heart homogenate. Bars represent mean ± S.E.M for n = 4. *Denotes statistically significant difference from respective saline control as determined by Fisher's least significant difference (LSD) method (a = 0.05).
Humana Press Volume 5, 2005 of the net accumulation of lipids in the serum of DOX treated rats. We have noted a milky and slightly more viscous serum in rats following chronic DOX treatment; however, we have yet to determine whether this reflects a change in the serum lipid profile (unpublished observations). Regardless, a treatment-related increase in lipid concentration combined with an increase carrying capacity for lipid-soluble a-tocopherol could account for the observed increase in serum a-tocopherol concentration observed for DOX-treated rats. In this case, one would expect the elevated serum a-tocopherol to temper any DOX-related oxidation of serum lipids or proteins, which we did not investigate in the present study. Unfortunately, prevention of the accumulation of oxidized cardiac proteins in whole heart tissue was the only indication of therapeutic efficacy of TOCO dietary supplementation. Despite successful enrichment of whole heart and mitochondrial membranes, dietary TOCO failed to prevent the DOX-induced lower heart and body weights, the inhibition of cardiac mitochondrial respiration and calcium-loading capacity, or the associated cardiac histopathology. Consequently, it may be concluded that either this particular antioxidant supplementation failed to protect against oxidative damage, which results in mitochondrial dysfunction and tissue histopathology, or that the oxidative tissue damage associated with DOX-induced cardiac toxicity is, by itself, inconsequential to the ultimate development of the mitochondrial cardiomyopathy.
